埃尔琴提供调节肥胖的健康益处:成分分析,网络药理学和实验验证实验
Longfei Zhang1,2, Xiaoxiao Liu1, Mingze Xu1
1College of Food Science and Technology Yangzhou University Yangzhou China.
Food science & nutrition
|August 7, 2025
概括
埃尔肯 (ECT) 显示出减肥的潜力,并改善了肥胖患者的脂质概况. 它通过通过LPS-TLR4/MyD88/NF-κB通路减少氧化应激和炎症来起作用.
科学领域:
- 传统中国医药 传统中国医药
- 药理学 药理学是指药理学的学科.
- 代谢性疾病研究研究
背景情况:
- 埃尔肯 (ECT) 是一种草药配方,对代谢性疾病有潜在的治疗应用.
- ECT对简单肥胖的具体影响和潜在机制在很大程度上仍未得到研究.
研究的目的:
- 阐明ECT在治疗简单肥胖症中的监管效应和物质基础.
- 预测和验证ECT对肥胖的行动中涉及的潜在目标和途径.
主要方法:
- 用组件分析和网络药理学来预测ECT的目标和肥胖的途径.
- 用分子对接来评估关键ECT化合物的结合亲和力.
- 动物模型被用来验证预测的治疗效果和机制.
主要成果:
- 确定了93个化合物和221个ECT和肥胖之间的重叠目标.
- ECT可以调节脂质代谢,氧化应激和免疫反应.
- 关键的ECT组件对氧化应激和免疫标志物具有强烈的结合.
- 通过LPS-TLR4/MyD88/NF-κB通路,ECT的使用导致体重减轻,脂质降低和减轻肝氧化应激和全身炎症.
结论:
- 在简单肥胖症中,ECT显示了体重管理和脂质调节的巨大潜力.
- 这项研究提供了对ECT抗肥胖作用的机制性理解,涉及氧化应激和炎症通路.
- 可以将ECT开发为一种功能性食物,用于管理简单的肥胖症.
更多相关视频
相关概念视频
Regulation of Food Intake
2.8K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
2.8K
Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324


